By Healio News –
Top-line results of a phase 2 clinical trial for an adipose-derived autologous mesenchymal stem cell therapy to address mild to moderate relapsing-remitting MS found the treatment improved mental and physical health at 52 weeks.
According to a press release by Hope Biosciences, the study met its primary endpoint of change in both physical and mental health for the treatment group compared with the placebo group as measured by the MS Quality of Life-54 Instrument, Physical and Mental Health Composite Scores.
